Idzior-Waluś B
Katedry i Kliniki Chorób Metabolicznych, Collegium Medicum, Uniwersytetu Jagieliońskiego w Krakowie.
Przegl Lek. 1996;53(9):653-9.
Hyperlipoproteinemia is one of the main coronary risk factors. Lipid metabolism disorders occur in about 40-60% of patients with NIDDM. Hyperlipidemia in diabetics is related to diabetes control, presence of diabetic nephropathy, diet, some drugs and genetic factors. Lipid metabolism disorders in NIDDM comprise qualitative changes--usually increase of serum triglyceride concentration and decrease of HDL--cholesterol, and qualitative changes of lipoprotein composition, glycation and oxidation. The first steps of hypolipemic therapy are good control of diabetes, reduction of overweight, hypolipidemic diet, and if a goal level is not achieved--farmacotherapy. Hypolipidemic treatment should be relevant in reduction of cardiovascular diseases in diabetic patients.
高脂蛋白血症是主要的冠状动脉危险因素之一。约40%-60%的非胰岛素依赖型糖尿病(NIDDM)患者存在脂质代谢紊乱。糖尿病患者的高脂血症与糖尿病控制情况、糖尿病肾病的存在、饮食、某些药物及遗传因素有关。NIDDM中的脂质代谢紊乱包括质的变化,通常是血清甘油三酯浓度升高和高密度脂蛋白胆固醇降低,以及脂蛋白组成、糖基化和氧化的质的变化。降血脂治疗的首要步骤是良好地控制糖尿病、减轻体重、采用降血脂饮食,如果未达到目标水平则进行药物治疗。降血脂治疗对于降低糖尿病患者的心血管疾病风险具有重要意义。